ESR1 and breast cancer: The combination of OncotypeDX and PAM50 gene panels (which provide a prediction score of temporal recurrence in subjects with estrogen-receptor-positive, HER2- BC) [72] and imaging phenotype trough radiomics has been demonstrated to strengthen the prediction significance of the above-mentioned molecular profiles [73,74].